Pharmacokinetics, disposition, and metabolism of bicifadine in the mouse, rat, and monkey

Drug Metabolism and Disposition

Volumn 36, Issue 2, 2008, Pages 241-251

  Musick, Timothy J ^a   Gohdes, Mark ^a   Duffy, Andrea ^a   Erickson, David A ^a   Krieter, Philip A ^b  

^a 206 Carnegie Center   (United States)

^b DOV Pharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICIFADINE; DOV 255828; DRUG METABOLITE; GLUCURONIDE; LACTAM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG URINE LEVEL; FEMALE; MALE; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANALGESICS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BILE; BLOOD PROTEINS; BRAIN; FECES; FEMALE; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED STRAINS; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; MACACA FASCICULARIS; MUS; RATTUS;

EID: 38749119372     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017863     Document Type: Article

References (11)

1. Basile AS, Janowsky A, Golembiowska K, Kowalska M, Tam E, Benveniste M, Popik P, Nikiforuk A, Krawczyk M, Nowak G, et al. (2007) Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J Pharmacol Exp Ther 321:1208-1225.
2. Belleau B and Moran J (1963) Deuterium isotope effects in relation to the chemical mechanism of monoamine oxidase. Ann N Y Acad Sciences 107:822-839.
3. Cesura AM and Pletscher A (1992) The new generation of monoamine oxidase inhibitors. Prog Drug Res 38:171-297.
4. Compernolle F, Van Hees GP, Blanckaert N, and Heirwegh KP (1978) Glucuronic acid conjugates of bilirubin-IXalpha in normal bile compared with post-obstructive bile. Transformation of the 1-O-acylglucuronide into 2-, 3-, and 4-O-acylglucuronides. Biochem J 171:185-201.
5. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
6. Epstein JW, Osterberg AC, and Regan BA (1982) Bicifadine: nonnarcotic analgesic activity of 1-aryl-3-azabicyclo[3.1.0]hexanes. NIDA Res Monograph 41:93-98.
7. Erickson DA, Hollfelder S, Tenge J, Gohdes M, Burkhardt JJ, and Krieter PA (2007) In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human. Drug Metab Dispos 35:2232-2241.
8. Hasegawa J, Smith PC, and Benet LZ (1982) Apparent intramolecular acyl migration of zomepirac glucuronide. Drug Metab Dispos 10:469-473.
9. Janssen FW, Kirkman SK, Fenselau C, Stogniew M, Hofmann BR, Young EM, and Ruelius HW (1982) Metabolic formation of N- and O-glucuronides of 3-(p-chlorophenyl)thiazolo[3,2-a]benzimidazole-2-acetic acid. Rearrangement of the 1-O-acyl glucuronide. Drug Metab Dispos 10:599-604.
10. Riff D, Huang N, Czobor P, and Stern W (2006) A five-day, multi-center, randomized, placebo-controlled, double-blind, efficacy and safety study of bicifadine and tramadol versus placebo in the treatment of postoperative bunionectomy pain. J Pain 7 (Suppl 2):S40.
11. Stern W, Czobor P, Stark J, and Krieter P (2005) Relationship between plasma bicifadine levels and analgesic effect in a dental pain model, in Abstracts: 11th World Congress on Pain; 2005 Aug 21-26; Sydney, Australia; pp 111, International Association for the Study of Pain, Seattle.